On my own cancer adventure I have discovered many treatment options for cancer. Of these, one of the rising stars is off-label drug treatments. Oncology Clinics are now prescribing these treatments  and they are proving to be very successful. Care Oncology in London, which is NHS approved, has been seeing good results in the treatment of advanced cancers.
The most commonly recommended drugs are doxycyline, mebendazole, metformin, and atorvastatin. These are drugs that have been available for decades, and over that time it was observed that they had cancer mitigating effects. When combined into a ‘cocktail’ these cancer mitigating effects become significant.
So how do an antibiotic, dewormer, diabetes medication and a statin work collectively to kill cancer?
Cancer proliferates via multiple mechanisms. These include abnormal cell signaling and a highly adaptive metabolism. Cancer stem cells are able to switch metabolic pathways. As an example, if the glucose pathway is shut down the stem cells will switch to a fat or protein pathway. This metabolic flexibility makes them very difficult to kill. Abnormal cell signalling enables cancer to proliferate. This means that a successful treatment requires all metabolic pathways to be inhibited simultaneously, while also disrupting the abnormal cell signalling. This can be accomplished by combining doxycycline, metformin, mebendazole and atorvastatin into a single protocol.
Doxycycline is an antibiotic that has been in use for decades and so drug safety is well understood. Its effect on cancer stem cells is to induce metabolic inflexibility by chronically inhibiting mitochondrial biogenesis.   It is also a MMP-9 inhibitor. Its ability to inhibit Fatty Acid Oxidation (FAO) is especially valuable in treating fat driven cancers like prostate and pancreatic cancer. Doxycycline has been demonstrated to be very effective when combined with high dose intravenous Vitamin C. 
Metformin is a drug treatment for type 2 diabetes. It is well known for its effects on cancer stem cells, including its impact on mitochondrial respiration and decreased insulin/IGF-1 receptor-mediated activation of the PI3K pathway  and inhibition of abnormal cell signalling .
Mebendazole is an anthelmintic drug historically used for the treatment of pinworms. It is widely available as an over the counter medication. It has multiple effects on cancer – inhibiting abnormal cell signalling, glucose uptake and has been demonstrated to be effective in the treatment of brain cancers . Mebendazole is capable of inducing apoptosis (cancer cell death) in a range of cancers, with leukaemia cell lines showing the highest level of sensitivity. 
Atorvastatin is normally prescribed for high cholesterol associated with heart disease. It has been known for 100 years that cholesterol accumulates in cancerous tissue and plays a critical role in cancer progression.  While we can argue about the relationship between heart disease and cholesterol there is no arguing the potent effect cholesterol has on cancer progression – and notably some of the worst cancers – leukemia, lymphoma, multiple myeloma, hepatic (liver), pancreatic, esophageal and prostate cancers.  The effects of cholesterol and the associated mevalonate pathway are quite complex.  Atorvastatin can mitigate these effects, and avoiding dietary intake of cholesterol is also valuable. 
The net effect of this combination of drugs is to inhibit all metabolic pathways simultaneously while also disrupting multiple abnormal cell signalling pathways.
Will this off label drug protocol work for your type of cancer?
There is an accumulation of evidence that this off-label drug protocol works, but like any treatment, it doesn’t work for everyone all the time. So should you try it or not? Safety is well established. Efficacy comes down to delivery – the ultimate problem for all anti-cancer drugs. In other words, will the drug/s reach the cancer cells in order to kill them? The answer to that question depends on where the cancer is.
Cancer drugs may work best when there is ready access to the cancer. For example, colon cancer – swallow the drugs and they go straight to target. If the cancer is in a lymph node you may have much more of an issue. If we are talking about a tumour in a lymph node in the groin (typical of prostate cancer) then the answer would probably be no – the lymphatic system pumps upward and so drugs taken orally just aren’t going to get there, notably in a quantity that could make a difference. (There are alternate protocols for this scenario).
It may be that the best scenario for this off-label drug protocol is primary cancers with a good blood supply – for example liver cancer. However there is evidence that a wide range of late stage cancers are being stopped. You may want to research this for yourself. Jane McClelland’s book “How to Starve Cancer” is probably the benchmark for discussion on this subject.
I will cover protocols for cancers in the lymphatic system and bone in another post.
You may be interested in personal coaching – you can check that out on my Coaching Page.